Avita Therapeutics' stock soared 14.18% intraday following the release of positive interim data from a key clinical study.
The surge comes after the company reported interim results from its Cohealyx-I multi-center study, which showed a significant reduction in the mean time to skin grafting for patients with full-thickness wounds. The data indicated a mean time of 13.6 days compared to a 33.2-day real-world benchmark.
The positive clinical outcomes, including a median time to grafting of 11 days, are seen as a promising development for the company's wound care platform, driving investor optimism regarding its potential market application and future commercial success.